Predictive value of elevated soluble CD40 ligand in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction
- PMID: 25004238
- DOI: 10.1097/MCA.0000000000000142
Predictive value of elevated soluble CD40 ligand in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction
Abstract
Objectives: The aim of this study was to evaluate the prognostic value of soluble CD40 ligand (sCD40L) in patients with ST-segment elevation myocardial infarction (STEMI) undergoing a primary percutaneous coronary intervention (PCI).
Background: The prognostic value of sCD40L has been documented in patients with acute coronary syndrome; however, its value in acute STEMI remains unclear.
Materials and methods: We prospectively enrolled 499 consecutive STEMI patients (397 men, 102 women) undergoing primary PCI. The study population was divided into tertiles on the basis of admission sCD40L values. The high sCD40L group (n=168) included patients with a value in the third tertile (≥0.947 mg/l) and the low sCD40L group (n=331) included patients with a value in the lower two tertiles (<0.947 mg/l). Clinical characteristics and in-hospital and 1-year primary PCI outcomes were analyzed.
Results: The patients in the high sCD40L group were older (mean age 57.3±12.7 vs. 54.8±11.9, P=0.029). Higher in-hospital and 1-year all-cause mortality rates were observed in the high sCD40L group (7.7 vs. 3.3%, P=0.029; 16.1 vs. 4.8%, P<0.001, respectively). The results of Cox multivariate analysis indicated that a high sCD40L value at admission (>0.947 mg/l) is a powerful independent predictor of 1-year all-cause mortality (odds ratio: 3.68; 95% confidence interval: 1.54-8.77; P=0.003).
Conclusion: The results of this study suggest that a high sCD40L level at admission is associated with increased in-hospital and 1-year all-cause mortality rates in patients with STEMI undergoing primary PCI.
Comment in
-
Prognostic utility of the soluble CD40 ligand in acute coronary syndrome.Coron Artery Dis. 2014 Nov;25(7):548-9. doi: 10.1097/MCA.0000000000000155. Coron Artery Dis. 2014. PMID: 25248136 No abstract available.
Similar articles
-
Predictive value of elevated cystatin C in patients undergoing primary angioplasty for ST-elevation myocardial infarction.J Crit Care. 2013 Oct;28(5):882.e13-20. doi: 10.1016/j.jcrc.2013.03.004. Epub 2013 May 14. J Crit Care. 2013. PMID: 23683571
-
Predictive value of elevated D-dimer in patients undergoing primary angioplasty for ST elevation myocardial infarction.Blood Coagul Fibrinolysis. 2013 Oct;24(7):704-10. doi: 10.1097/MBC.0b013e3283610396. Blood Coagul Fibrinolysis. 2013. PMID: 23571687 Clinical Trial.
-
Long-term prognostic value of elevated pentraxin 3 in patients undergoing primary angioplasty for ST-elevation myocardial infarction.Coron Artery Dis. 2015 Nov;26(7):592-7. doi: 10.1097/MCA.0000000000000280. Coron Artery Dis. 2015. PMID: 26061437
-
The relationship between γ-glutamyl transferase levels and the clinical outcomes in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.Coron Artery Dis. 2013 Jun;24(4):272-8. doi: 10.1097/MCA.0b013e328360d131. Coron Artery Dis. 2013. PMID: 23542158
-
Prognostic utility of neutrophil gelatinase-associated lipocalin in predicting mortality and cardiovascular events in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention.J Am Coll Cardiol. 2012 Jul 24;60(4):339-45. doi: 10.1016/j.jacc.2012.04.017. J Am Coll Cardiol. 2012. PMID: 22813613
Cited by
-
CD40/CD40L and Related Signaling Pathways in Cardiovascular Health and Disease-The Pros and Cons for Cardioprotection.Int J Mol Sci. 2020 Nov 12;21(22):8533. doi: 10.3390/ijms21228533. Int J Mol Sci. 2020. PMID: 33198327 Free PMC article. Review.
-
Platelets in inflammation and atherogenesis.Front Immunol. 2015 Mar 6;6:98. doi: 10.3389/fimmu.2015.00098. eCollection 2015. Front Immunol. 2015. PMID: 25798138 Free PMC article. Review.
-
Decreased Platelet Inhibition by Thienopyridines in Hyperuricemia.Cardiovasc Drugs Ther. 2021 Feb;35(1):51-60. doi: 10.1007/s10557-020-07058-x. Epub 2020 Aug 26. Cardiovasc Drugs Ther. 2021. PMID: 32845391 Free PMC article.
-
The CD40-CD40L Dyad as Immunotherapeutic _target in Cardiovascular Disease.J Cardiovasc Transl Res. 2021 Feb;14(1):13-22. doi: 10.1007/s12265-020-09994-3. Epub 2020 Mar 28. J Cardiovasc Transl Res. 2021. PMID: 32222950 Free PMC article. Review.
-
The Biomarkers for Acute Myocardial Infarction and Heart Failure.Biomed Res Int. 2020 Jan 17;2020:2018035. doi: 10.1155/2020/2018035. eCollection 2020. Biomed Res Int. 2020. PMID: 32016113 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous